This bill requires New Jersey Medicaid managed care organizations to prioritize lower-cost generic and biosimilar drugs over their brand-name counterparts. Specifically, it mandates that patients prescribed a brand drug for the first time receive a biosimilar if one is available, unless a healthcare provider appeals this decision. Additionally, the law forces insurers to place cheaper generics and biosimilars on their drug formularies with better pricing and fewer access restrictions, such as prior authorizations, whenever these alternatives are less expensive than the original products. The bill also improves transparency by requiring these organizations to publish their drug lists online in an easy-to-find format that does not require users to create an account.
This bill requires health benefits plans in New Jersey that use pharmacy benefits managers to allow any pharmacy meeting standard contract terms to join their network. The Commissioner of Banking and Insurance will define these terms as reasonable and relevant by reviewing existing contracts and ensuring reimbursement fees cover pharmacy ingredient and operational costs. The law applies to new or renewed contracts between health plans and pharmacy managers starting thirteen months after it is enacted.
This bill requires healthcare platforms in New Jersey to advise and consult with consumers regarding the therapeutic values, hazards, and uses of drugs, biologicals, and devices they send. The law mandates that these platforms provide this information using electronic methods such as email, text messaging, or video calls. It directly affects online services that allow members to obtain discounts on medications or access telemedicine services. The legislation clarifies that these platforms must follow existing pharmacy practice standards when communicating with users about their prescriptions and medical devices.
This New Jersey bill requires pharmacy benefits managers to be paid a flat, itemized service fee rather than commissions tied to drug prices or sales volumes. It directly affects insurance carriers and pharmacy benefits managers by mandating that their compensation reflects the fair market value of actual services provided, excluding any pass-through costs to patients. The law also establishes strict reporting rules, requiring carriers to include detailed actuarial memorandums and supporting records in their rate filings to verify these fee calculations. By prohibiting fees based on drug costs, rebates, or referral volumes, the measure aims to ensure transparency and prevent conflicts of interest in prescription drug benefit administration.
This bill allows pharmacists in New Jersey to provide an emergency supply of certain chronic maintenance medications without a current prescription when a patient cannot reach their doctor for a refill. To qualify, the pharmacy must have a prior prescription on file, the pharmacist must attempt to contact the prescribing practitioner without success, and the medication cannot be a controlled substance. The emergency supply is limited to a 30-day amount and cannot be provided to the same patient more than once within a 12-month period, with full documentation required. Pharmacists and their employers are protected from civil liability unless they act with gross negligence or willful misconduct. The Board of Pharmacy will establish specific rules to implement these provisions.
This bill requires pharmacy benefits managers to provide detailed financial reports to health plan sponsors every six months. The reports must include information about drug costs, payments, rebates, and out-of-pocket spending for each medication covered under the plan. The legislation affects pharmacy benefits managers, health plan sponsors, and drug manufacturers by mandating transparency in how these entities handle drug pricing and compensation. Reports must be presented in plain language and machine-readable formats to ensure plan sponsors can easily understand the financial details.
This bill creates a three-year pilot program in New Jersey's Medicaid system to test a value-based payment approach for certain high-cost prescription drugs. Under the program, the state would negotiate with drug manufacturers to tie reimbursement amounts to observed patient outcomes rather than just the price of the medication. The initiative would focus on at least three expensive drugs with measurable health results and would require Medicaid managed care organizations to participate. At the end of the three-year period, the state would report findings to the Governor and Legislature to determine whether to expand or modify the program.
This bill requires insurance carriers in New Jersey to cover prescription drugs for serious mental illnesses like schizophrenia, bipolar disorder, and PTSD without requiring prior authorization or step therapy. It directly affects individuals with these conditions who need mental health coverage through health plans, ensuring they can access necessary medications without unnecessary administrative hurdles. The law also mandates that insurers report annually on how they develop medical necessity criteria for mental health and substance use disorder treatments, increasing transparency in coverage decisions. Additionally, carriers must provide information about in-plan exceptions when qualified providers are not available in their network.
This bill authorizes New Jersey to quickly procure a pharmacy benefits manager for its State Health Benefits Program and School Employees' Health Benefits Program through an expedited, non-advertised process. The State will use automated reverse auction technology to compare vendor pricing and an electronic system to review pharmacy claims in real time, with the goal of securing competitive rates and improving oversight. The legislation modifies standard procurement rules to shorten review timelines, allow online advertising instead of formal publication, and exclude certain pricing disclosures during negotiations. A report detailing the auction results, savings achieved, and any procedural deviations must be submitted to the Governor and Legislature within 60 days of contract award.
This bill requires four-year public colleges in New Jersey to create and maintain a reproductive health services plan for students, while county colleges must establish a referral network to off-campus reproductive health providers. The plan must ensure access to contraception (including emergency contraception via vending machines or 24-hour options), STI/HIV testing/treatment, prenatal care, and abortion services through campus clinics or verified referrals. It specifically addresses student barriers like limited pharmacy access and lack of transportation by mandating campus-based options and community referrals. The bill does not require institutions to directly provide abortion services but ensures students can access care through structured pathways.
